Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities ( Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany )
14 Jun 2019

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
13 Jun 2019

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019

Advances in PARP inhibitor use for metastatic breast cancer

Prof Hope Rugo - University of California, San Francisco, USA
Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

Prof Hope Rugo - University of California, San Francisco, USA
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019

The future of PARP inhibitors in metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA
The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
12 Jun 2019

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Jun 2019

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Jun 2019

Managing metastatic breast cancer and beyond using PARP inhibitors

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019

Updates in metastatic and early-stage breast cancer

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies

Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )
10 Jun 2019